The Effect of Hibiscus Sabdariffa L. Tea on Blood Pressure

NCT ID: NCT00175110

Last Updated: 2009-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

66 participants

Study Classification

INTERVENTIONAL

Study Completion Date

2007-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to find out whether the plant compounds present in Hibiscus sabdariffa, a plant commonly used in herbal tea blends and other beverages, will have a beneficial effect on blood pressure in people with mildly elevated blood pressure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

pre-hypertension mild hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

herbal therapy/botanical therapy (Hibiscus sabdariffa)

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Systolic blood pressure 120-150 mm Hg
* Diastolic blood pressure 95 mm Hg or less
* Body mass index (BMI) 18.5-34.9 kg/m2

Exclusion Criteria

* Smoking
* Use of medications that influence blood pressure
* Cardiovascular disease
* Chronic kidney disease
* Diabetes
* Regular use of vitamin C supplements (min 500 mg/day) within prior 30 days
* Regular strenuous aerobic activity greater than 30 min/day
* Excessive intake of caffeine or alcohol
* Pregnancy within last 6 months or during study period
* Abnormal complete blood count (CBC), urinalysis or electrocardiogram (EKG)
Minimum Eligible Age

30 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Celestial Seasonings

INDUSTRY

Sponsor Role collaborator

Tufts Medical Center

OTHER

Sponsor Role collaborator

Tufts University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tufts University

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jeffrey B Blumberg, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Tufts Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University

Boston, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

McKay DL, Chen CY, Saltzman E, Blumberg JB. Hibiscus sabdariffa L. tea (tisane) lowers blood pressure in prehypertensive and mildly hypertensive adults. J Nutr. 2010 Feb;140(2):298-303. doi: 10.3945/jn.109.115097. Epub 2009 Dec 16.

Reference Type DERIVED
PMID: 20018807 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PV3727

Identifier Type: -

Identifier Source: org_study_id